4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1710-1492
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry ; volume:13 ; number:1 ; day:26 ; month:7 ; year:2017 ; pages:1-6 ; date:12.2017
Allergy, asthma and clinical immunology ; 13, Heft 1 (26.7.2017), 1-6, 12.2017
- Schlagwort
-
Atemwegskrankheit
Atemnot
- Urheber
-
Snelder, S. M.
- Beteiligte Personen und Organisationen
-
Weersink, E. J. M.
Braunstahl, G. J.
SpringerLink (Online service)
- DOI
-
10.1186/s13223-017-0206-9
- URN
-
urn:nbn:de:1111-2017100615588
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Snelder, S. M.
- Weersink, E. J. M.
- Braunstahl, G. J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Severe asthma and the omalizumab option
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung
Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
Poster 1012: Safety and efficacy of omalizumab in 10 children with asthma and other allergic comorbidities
Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
Dermatomyositis associated with omalizumab therapy for severe asthma: a case report
Comparison of extended intervals and dose reduction of omalizumab for asthma control
Omalizumab: clinical use for the treatment of an adolescent with difficult asthma
Severe asthma and the omalizumab option
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung
Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
Poster 1012: Safety and efficacy of omalizumab in 10 children with asthma and other allergic comorbidities
Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
Dermatomyositis associated with omalizumab therapy for severe asthma: a case report
Comparison of extended intervals and dose reduction of omalizumab for asthma control
Omalizumab: clinical use for the treatment of an adolescent with difficult asthma
Severe asthma and the omalizumab option
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
Omalizumab in patients with severe asthma and persistent sputum eosinophilia
Omalizumab-Therapie bei Jugendlichen mit schwerem allergischen Asthma – eine Anwendungsbeobachtung
Omalizumab-Therapie bei Jugendlichen mit schwerem allergischem Asthma – eine Anwendungsbeobachtung
Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy
Poster 1012: Safety and efficacy of omalizumab in 10 children with asthma and other allergic comorbidities
Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
Dermatomyositis associated with omalizumab therapy for severe asthma: a case report
Comparison of extended intervals and dose reduction of omalizumab for asthma control